- Home
- STAI vs RANI Comparison
STAI vs RANI Comparison
Compare STAI & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- RANI
- Stock Information
- Founded
- STAI 2011
- RANI 2012
- Country
- STAI United States
- RANI United States
- Employees
- STAI N/A
- RANI N/A
- Industry
- STAI
- RANI Medicinal Chemicals and Botanical Products
- Sector
- STAI
- RANI Health Care
- Exchange
- STAI Nasdaq
- RANI Nasdaq
- Market Cap
- STAI 24.6M
- RANI 24.2M
- IPO Year
- STAI N/A
- RANI 2021
- Fundamental
- Price
- STAI $0.46
- RANI $2.15
- Analyst Decision
- STAI
- RANI Strong Buy
- Analyst Count
- STAI 0
- RANI 6
- Target Price
- STAI N/A
- RANI $8.67
- AVG Volume (30 Days)
- STAI 14.9M
- RANI 50.4M
- Earning Date
- STAI 09-17-2025
- RANI 11-07-2025
- Dividend Yield
- STAI N/A
- RANI N/A
- EPS Growth
- STAI N/A
- RANI N/A
- EPS
- STAI N/A
- RANI N/A
- Revenue
- STAI $1,249,524.00
- RANI $1,200,000.00
- Revenue This Year
- STAI N/A
- RANI N/A
- Revenue Next Year
- STAI N/A
- RANI N/A
- P/E Ratio
- STAI N/A
- RANI N/A
- Revenue Growth
- STAI 139.30
- RANI N/A
- 52 Week Low
- STAI $0.35
- RANI $0.39
- 52 Week High
- STAI $9.07
- RANI $3.87
- Technical
- Relative Strength Index (RSI)
- STAI 44.37
- RANI 62.99
- Support Level
- STAI $0.48
- RANI $1.42
- Resistance Level
- STAI $0.73
- RANI $3.87
- Average True Range (ATR)
- STAI 0.07
- RANI 0.61
- MACD
- STAI -0.01
- RANI 0.02
- Stochastic Oscillator
- STAI 2.07
- RANI 49.24
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.